Erdafitinib, also known as JNJ-42756493 and marketed under the brand name Balversa, is an orally active small-molecule kinase inhibitor developed for targeted cancer therapy. It belongs to the fibroblast growth factor receptor (FGFR) inhibitor class and has an important role in the treatment of selected patients with advanced urothelial carcinoma. By targeting specific molecular pathways associated with tumor growth, Erdafitinib represents an important development in precision oncology and targeted pharmaceutical research.
With increasing interest in molecularly targeted therapies, Erdafitinib is also a relevant compound for pharmaceutical research, drug development, and analytical studies.
Product Overview
Product Name: Erdafitinib
CAS Number: 1346242-81-6
Molecular Formula: C25H30N6O2
Molecular Weight: 446.56 g/mol
Synonym: JNJ-42756493
Drug Class: Fibroblast Growth Factor Receptor (FGFR) Inhibitor
Appearance: Yellow powder, as described in the FDA product labeling
Erdafitinib is a selective, orally available inhibitor of the FGFR family. Its molecular structure incorporates quinoxaline, pyrazole, and dimethoxyphenyl groups, contributing to its interaction with FGFR kinase targets. The compound is characterized by limited aqueous solubility, making solubility and formulation behavior important considerations in pharmaceutical development.
Mechanism of Action
Fibroblast growth factor receptors are receptor tyrosine kinases involved in several cellular processes, including cell proliferation, differentiation, survival, and tissue development. Genetic alterations in FGFR signaling pathways can contribute to abnormal cellular growth and tumor progression.
Erdafitinib works by inhibiting the enzymatic activity of FGFR1, FGFR2, FGFR3, and FGFR4. This action suppresses FGFR phosphorylation and downstream signaling pathways. In cancer cells carrying relevant FGFR alterations, inhibition of these pathways can reduce cell viability and interfere with tumor growth.
The compound has demonstrated activity in experimental models involving FGFR-related genetic alterations, including mutations, amplifications, and gene fusions. Its targeted mechanism makes it particularly relevant to biomarker-driven oncology research.
Applications of Erdafitinib
Targeted Treatment of Urothelial Carcinoma
Erdafitinib is approved in the United States for the treatment of eligible adult patients with locally advanced or metastatic urothelial carcinoma harboring susceptible FGFR3 genetic alterations, following prior systemic therapy. This application highlights the importance of molecular testing in selecting patients who may benefit from targeted treatment.
FGFR-Related Cancer Research
As an inhibitor of FGFR1–4, Erdafitinib is a useful compound in research investigating FGFR signaling and its involvement in cancer biology. It can support studies of receptor activation, downstream signaling, tumor cell proliferation, and molecular mechanisms associated with FGFR alterations.
Drug Discovery and Development
Erdafitinib provides a reference compound for the development and evaluation of new FGFR-targeting molecules. Researchers can use it in comparative studies involving kinase inhibition, molecular selectivity, structure–activity relationships, and potential improvements in therapeutic performance.
Pharmaceutical and Analytical Research
Erdafitinib is relevant to analytical method development, reference testing, impurity profiling, and pharmaceutical formulation studies. Its physicochemical characteristics, including limited water solubility, make it a useful subject for research into solubility enhancement, dissolution behavior, and drug delivery strategies.
Key Benefits and Research Value
Targeted Mechanism: Inhibits FGFR1, FGFR2, FGFR3, and FGFR4, supporting research into FGFR-driven disease pathways.
Clinical Relevance: Has an established therapeutic application in selected patients with FGFR3-altered advanced urothelial carcinoma.
Research Versatility: Supports oncology research, kinase inhibition studies, and drug discovery programs.
Defined Chemical Identity: Its established molecular formula, molecular weight, and CAS number facilitate identification and analytical characterization.
Formulation Research Potential: Its limited aqueous solubility provides a relevant subject for pharmaceutical formulation and drug delivery investigations.
Quality and Sourcing Considerations
For pharmaceutical research and development, the quality of Erdafitinib is essential. Buyers should evaluate the product's identity, assay, impurity profile, residual solvents, water content, and analytical documentation according to the intended application.
Appropriate quality documentation may include a Certificate of Analysis (COA), analytical testing data, and a Safety Data Sheet (SDS). Depending on the project, additional requirements may include validated analytical methods, batch consistency, and specific impurity controls.
When sourcing this compound, pharmaceutical companies, research laboratories, and drug development organizations should work with suppliers capable of providing clear specifications, reliable documentation, and responsive technical support.
LEAPChem: Your Partner for Pharmaceutical Research Chemicals
LEAPChem provides a broad portfolio of pharmaceutical chemicals, active pharmaceutical ingredients, intermediates, and research-related compounds for customers across the global pharmaceutical and life science industries.
With 20 years of experience in the chemical industry, LEAPChem serves more than 3,500 active customers across over 135 countries. Our portfolio includes more than 30,000 selected products, supported by a sourcing network and quality-focused supply management.
We emphasize product quality, supplier evaluation, documentation, and customer service to help simplify chemical purchasing. Whether for pharmaceutical research, analytical development, or specialized chemical sourcing, LEAPChem works to connect customers with suitable products and dependable supply solutions.
Conclusion
Erdafitinib (CAS 1346242-81-6) is an important FGFR-targeting kinase inhibitor with an established role in precision oncology. Its ability to inhibit FGFR1–4 makes it relevant to targeted treatment and a range of cancer research and drug development activities. As interest in biomarker-driven therapies continues to grow, compounds such as Erdafitinib remain significant in pharmaceutical research.
For customers seeking Erdafitinib and other specialized pharmaceutical chemicals, LEAPChem offers product sourcing support, quality-focused service, and access to a broad global chemical supply network.
For research and pharmaceutical development use. Erdafitinib is a prescription oncology medicine; clinical use must follow approved product labeling and the direction of qualified healthcare professionals.
